The authors aimed to evaluate safety and efficacy of sorafenib in the elderly population. Sorafenib showed similar results in terms of safety and efficacy in the elderly and younger HCC populations. Careful baseline evaluation is needed for patient’s selection in the elderly population, including discussion about antiplatelet therapy discontinuation and caution in PS1 patients, as well as active management of toxicity.

READ FULL ARTICLE Curated publisher From Mdlinx